BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

"Awaiting clarity on more funding to promote pharma R&D": Kotak Securities

03 February 2023 | Views

Purvi Shah, Deputy Vice President - Fundamental Research, Kotak Securities shares her reaction on Union Budget 2023-24



"Allocation for development of pharma industry has been increased from Rs 100 crore in FY23E to Rs 1250 crore in FY24E. I mpact of this will be that there will be new programmes to promote pharma R&D through centres of excellence. However, we would await clarity on where exactly these additional funds are going to be used."